Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 1 September 2016

    Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

  • 8 August 2016

    ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016

  • 27 July 2016

    Oryzon Initiates Multiple Ascending Dose Cohorts In ORY-2001 Phase 1 Clinical Trial

  • 5 July 2016

    Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

  • 6 June 2016

    ORYZON to Present at the JMP Securities Life Sciences Conference on June 22nd, 2016

  • 2 June 2016

    EpigenomicsNet features Oryzon CSO Tamara Maes on Epigenetic drug development

  • 18 May 2016

    ORYZON to extend its R&D collaboration on ORY-1001 until March 2017

  • 12 May 2016

    ORYZON Reports First Quarter 2016 Financial Results and Corporate Update

  • 4 May 2016

    ORYZON Closes € 10.5 Million (12.1 M USD) Debt Financing

  • 11 April 2016

    Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Current page 28
  • Page 29
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel